DocMorris Reports Strong Growth and Boosts Guidance for 2026

DocMorris AG has reported a significant growth momentum in its prescription (Rx) and digital services sectors during the first half of 2026, with revenue rising by 12.5%. The Rx segment saw a 38.3% increase, while digital services experienced a 71.4% surge. This positive trajectory has prompted an upward revision of the company's full-year revenue and adjusted EBITDA guidance.

CEO Walter Hess noted the improvement in revenue momentum and operational efficiency. CFO Daniel Wüest highlighted the increase in adjusted EBITDA by CHF 17.9 million. The growth in Rx was primarily driven by increased customer loyalty and new customer acquisition, contributing to expected full-year Rx growth of 40%.

Non-prescription (Non-Rx) digital services also showed considerable expansion, with platforms like TeleClinic witnessing a 48% rise in revenue. As a result, DocMorris anticipates digital services growth exceeding 50% for the year.

DocMorris adjusted its overall revenue growth guidance to 9-13% and aims for EBITDA breakeven in the latter half of 2026. The company remains optimistic yet cautious in its financial outlook.